Study of AG-270 in Participants With Advanced Solid Tumors or Lymphoma With MTAP Loss
This study will evaluate the safety, pharmacokinetics, pharmacodynamics, and clinical activity of AG-270 in participants with advanced solid tumors or lymphoma with homozygous MTAP deletion.
A Phase 1 Study of AG-270 in the Treatment of Subjects with Advanced Solid Tumors or Lymphoma with Homozygous Deletion of MTAP
- ClinicalTrials.gov Identifier: NCT03435250
- Protocol Number: 18-053
- Principal Investigator: Gerburg Wulf
- Principal Investigator: Central PIO
Contact the research team to learn more about this study.
Fields marked with asterisk (*) are required